Sabinsa Corp. expanded its IP portfolio with a patent (MX328842) granted in Mexico for its Boswellia serrata ingredient Boswellin PS.
Photo © Shutterstock.com/jovan vitanovski
Sabinsa Corp. (East Windsor, NJ) expanded its IP portfolio with a patent (MX328842) granted in Mexico for its Boswellia serrata ingredient Boswellin PS. A composition containing boswellic acids and polysaccharides from the Boswellia species, the patent applies to its property of downregulating pro-inflammatory markers.
“Inflammation is an underlying cause of many health conditions throughout the world,” said Muhammed Majeed, PhD, founder and chairman of Sabinsa, in a press release. “By applying modern research to ancient Ayurvedic knowledge Sabinsa has been able to provide natural solutions, including the Boswellin PS ingredient, to this common condition.”
Boswellin PS was also awarded with a patent grant in Australia, Canada, Eurasia, and Taiwan.